South Korean (KOSPI) Biotech Industry Analysis
UpdatedJan 30, 2023
DataAggregated Company Financials
Companies102
- 7D2.2%
- 3M-4.3%
- 1Y-21.8%
- YTD3.3%
The Biotech industry is up 2.2% in the last week, with Celltrion up 2.6%. However, the industry is down 22% over the past year. Earnings are forecast to grow by 18% annually.
Industry Valuation and Performance
Has the South Korean Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 30 Jan 2023 | ₩59.9t | ₩11.3t | ₩970.8b | 24.5x | 61.7x | 5.3x |
| Wed, 28 Dec 2022 | ₩60.0t | ₩11.4t | ₩678.5b | 23.9x | 88.5x | 5.3x |
| Fri, 25 Nov 2022 | ₩61.2t | ₩11.0t | ₩298.7b | 20.9x | 204.9x | 5.6x |
| Sun, 23 Oct 2022 | ₩56.9t | ₩10.8t | ₩348.0b | 19.2x | 163.5x | 5.3x |
| Tue, 20 Sep 2022 | ₩60.7t | ₩10.8t | ₩495.4b | 22.3x | 122.4x | 5.6x |
| Thu, 18 Aug 2022 | ₩74.4t | ₩10.7t | ₩578.1b | 24.4x | 128.7x | 7x |
| Sat, 16 Jul 2022 | ₩71.2t | ₩10.7t | ₩597.6b | 24.5x | 119.1x | 6.7x |
| Mon, 13 Jun 2022 | ₩66.4t | ₩10.6t | ₩626.3b | 27.1x | 106x | 6.2x |
| Wed, 11 May 2022 | ₩65.5t | ₩10.0t | ₩866.3b | 25x | 75.6x | 6.6x |
| Fri, 08 Apr 2022 | ₩73.1t | ₩10.0t | ₩898.1b | 27.2x | 81.4x | 7.3x |
| Sun, 06 Mar 2022 | ₩73.6t | ₩9.4t | ₩769.1b | 34.5x | 95.7x | 7.8x |
| Tue, 01 Feb 2022 | ₩72.4t | ₩9.4t | ₩787.4b | 31.6x | 91.9x | 7.7x |
| Thu, 30 Dec 2021 | ₩92.5t | ₩9.4t | ₩787.4b | 40.2x | 117.4x | 9.9x |
| Sat, 27 Nov 2021 | ₩97.5t | ₩9.3t | ₩1.0t | 31.6x | 95.7x | 10.5x |
| Mon, 25 Oct 2021 | ₩97.4t | ₩9.2t | ₩986.0b | 39.8x | 98.8x | 10.6x |
| Wed, 22 Sep 2021 | ₩116.6t | ₩9.2t | ₩986.1b | 43.8x | 118.2x | 12.7x |
| Fri, 20 Aug 2021 | ₩116.5t | ₩9.3t | ₩909.7b | 48.9x | 128.1x | 12.5x |
| Fri, 04 Jun 2021 | ₩101.8t | ₩9.0t | ₩979.0b | 45.3x | 104x | 11.3x |
| Mon, 08 Mar 2021 | ₩89.7t | ₩8.2t | ₩501.3b | 44.6x | 179x | 10.9x |
| Thu, 10 Dec 2020 | ₩96.4t | ₩7.5t | ₩238.5b | 31.9x | 404.2x | 12.8x |
| Wed, 02 Sep 2020 | ₩93.9t | ₩6.7t | -₩13,176,736,074.00 | 51.4x | -7126.9x | 14x |
| Sat, 06 Jun 2020 | ₩63.0t | ₩6.1t | -₩304,564,934,452.00 | 46.5x | -206.9x | 10.4x |
| Tue, 10 Mar 2020 | ₩46.6t | ₩5.8t | -₩212,594,028,191.00 | 49.2x | -219.3x | 8x |
Price to Earnings Ratio
-219.9x
Current Industry PE
- Investors are optimistic on the South Korean Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 61.7x which is higher than its 3-year average PE of -464x.
- The 3-year average PS ratio of 9.5x is higher than the industry's current PS ratio of 5.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 25% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare industry?
| KR Market | 3.72% | |
| Healthcare | 1.93% | |
| Biotech | 2.17% | |
| Biotech | 2.17% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A302440 SK bioscienceLtd | ₩77.00k | 3.6% +₩207.3b | -53.3% | PE21.2x | |
| A068270 Celltrion | ₩163.70k | 0.7% +₩172.0b | 12.7% | PE40.7x | |
| A196170 ALTEOGEN | ₩35.10k | 3.2% +₩56.7b | -12.3% | PE438.4x | |
| A086900 Medy-Tox | ₩134.20k | 4.8% +₩37.9b | 22.3% | PE34.7x | |
| A263050 Eutilex.Co.Ltd | ₩6.43k | 7.9% +₩17.3b | -49.5% | PS1756.2x |